Xilio rebalances board classes, shareholders approve stock plan amendment

Xilio Therapeutics, Inc.

Daniel Curran re-elected Class II director, then resigned and reappointed Class III to equalize board classes; no compensation change.
Stockholders approved Amended and Restated 2021 Stock Incentive Plan, adding prefunded warrant shares to annual evergreen increase.
All four Class II director nominees and ratification of Ernst & Young as auditor approved at June 10, 2026 annual meeting.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Xilio Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

On June 10, 2026, the Company held the 2026 Annual Meeting. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters. 1. The Company’s stockholders elected Akintunde Bello, Ph.D., Daniel Curran, M.D., Robert Ross, M.D. and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Votes For Votes Withheld Broker Non-Votes Akintunde Bello, Ph.D. 3,652,015 130,437 1,279,671 Daniel Curran, M.D. 3,709,598 72,854 1,279,671 Robert Ross, M.D. 3,719,795 62,657 1,279,671 Yuan Xu, Ph.D. 3,716,549 65,903 1,279,671

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-269358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.